In this episode (21:02), Medicom’s correspondent covers 6 key updates from the annual meeting of The European Alliance of Associations for Rheumatology (EULAR 2023) held in Milan, Italy from 31 May – 3 June, 2023.
- Novel non-antibody fusion protein effective Sjögren’s syndrome
In the phase 2 ALISS trial presented as a Late Breaker, dazodalibep led to a significant reduction of the symptom burden in participants with Sjögren’s syndrome. These results support further development of the drug in a phase 3 trial. - HUNT study: DMARDs influence the fracture risk in RA
In a large population-based study, rheumatoid arthritis (RA) was associated with an almost 50% increased risk of major osteoporotic fractures (MOF) compared with non-RA. However, RA treated with biological disease-modifying antirheumatic drugs (DMARDs) showed no association with MOF. - Selective JAK1/TYK2 inhibition: a novel way to overcome tofacitinib resistance in RA?
According to a Chinese trial, therapy with an investigative JAK1/TYK2 inhibitor led to remission in a third of participants with difficult-to-treat rheumatoid arthritis (RA). Novel treatment options for these patients are urgently needed. - Breakthrough in patients with refractory gout: Novel 2-component infusion therapy controls serum urate levels
In the 2 similarly designed DISSOLVE I and DISSOLVE II trials, almost 50% of patients receiving infusions with a novel 2-drug combo were able to get their serum urate concentrations under control. With this agent, anti-drug antibody responses, usually limiting the use of uricase products, are hindered by nano-encapsulated rapamycin. - SSc patients with pre-capillary hypertension benefit from targeted DMARDs
Not immunosuppressive therapy per se, but treatment with targeted therapy demonstrated a significant protective effect on mortality or worsening in patients with systemic sclerosis (SSc) and pre-capillary pulmonary hypertension (precapPH). As these new results are based on registry data, randomised-controlled trials are now suggested for further evaluation. - In patients with PsA, inflammation extends to the vascular bed
Increased vascular inflammation has been found in patients with psoriatic arthritis (PsA) compared with healthy controls. The significant differences in the target-to-background ratio (TBR) of the aorta on PET/CT pointed to the presence of vascular inflammation in PsA.
Posted on
Previous Article
« Long-term success for CD19 CAR T-cell therapy in CLL Next Article
ASCO 2023 Highlights Podcast »
« Long-term success for CD19 CAR T-cell therapy in CLL Next Article
ASCO 2023 Highlights Podcast »
Table of Contents: EULAR 2023
Featured articles
Late-breaking Oral Abstracts
Selective JAK1/TYK 2 inhibitor effective in patients with difficult-to-treat RA
Novel 2-drug combo improves treatment possibilities for patients with refractory gout
Dazodalibep improves dryness, fatigue, and pain in patients with Sjögren’s syndrome with a high symptom burden
COVID-19: Young adults with auto-immune diseases have different risks than their healthy counterparts
RA in 2023
Poly-refractory RA: not common, but still present
AI almost as successful as experts in predicting early RA
Worse self-management in patients with inflammatory arthritis in the presence of comorbid anxiety or depression
Disease activity-guided dose reduction may be a long-term option for stable RA
Cardiovascular safety of JAK inhibitors: reassuring results from a real-world study
Spondylarthropathies: New Developments
AxSpA: Adalimumab biosimilar equally effective as IL-17 inhibitor in hindering radiographic progression
Vascular inflammation may be characteristic of PsA
Obesity in PsA is increasingly affecting male patients
PsA patients: highest risk of developing NAFLD
What is Hot in Osteoarthritis
Lorecivivint shows long-term benefits for severe knee OA
Methotrexate lowers pain in inflammatory hand OA
Systemic Sclerosis: State of the Art
Targeted DMARDs advantageous in SSc patients with pre-capillary pulmonary hypertension
Osteoporosis: New Data
Drugs for osteoporosis: time to reach fracture risk reduction varies
Romosozumab: the new option for glucocorticoid-induced osteoporosis with high fracture risk?
Best of the Posters
Therapy with biological DMARDs shows no correlation with fracture risk in RA
Basic Science
In vitro and in vivo studies confirm the role of regulatory volume decrease
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com